NewEdge Advisors LLC Boosts Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

NewEdge Advisors LLC boosted its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 26.0% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,372 shares of the company’s stock after purchasing an additional 2,140 shares during the period. NewEdge Advisors LLC’s holdings in TransMedics Group were worth $1,562,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of TMDX. Amalgamated Bank lifted its position in shares of TransMedics Group by 6.7% during the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock valued at $168,000 after buying an additional 70 shares in the last quarter. Pitcairn Co. lifted its stake in shares of TransMedics Group by 1.5% during the 1st quarter. Pitcairn Co. now owns 5,378 shares of the company’s stock valued at $398,000 after buying an additional 78 shares in the last quarter. Signaturefd LLC boosted its holdings in TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after buying an additional 93 shares during the period. Arizona State Retirement System boosted its holdings in TransMedics Group by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock worth $1,379,000 after buying an additional 186 shares during the period. Finally, International Assets Investment Management LLC purchased a new stake in TransMedics Group in the 2nd quarter worth $47,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other TransMedics Group news, insider Anil P. Ranganath sold 4,289 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $152.20, for a total value of $652,785.80. Following the sale, the insider now owns 8,893 shares in the company, valued at $1,353,514.60. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,948,714.31. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Anil P. Ranganath sold 4,289 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $152.20, for a total transaction of $652,785.80. Following the completion of the transaction, the insider now owns 8,893 shares of the company’s stock, valued at $1,353,514.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 64,205 shares of company stock valued at $10,089,374. Insiders own 7.00% of the company’s stock.

TransMedics Group Trading Down 3.4 %

Shares of TMDX opened at $138.97 on Friday. The company’s fifty day simple moving average is $156.02 and its 200-day simple moving average is $134.13. The company has a market cap of $4.64 billion, a P/E ratio of -408.74 and a beta of 1.99. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67. TransMedics Group, Inc. has a twelve month low of $36.42 and a twelve month high of $177.37.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The company had revenue of $114.30 million for the quarter, compared to analyst estimates of $98.84 million. During the same period in the prior year, the company posted ($0.03) EPS. The firm’s revenue for the quarter was up 117.7% on a year-over-year basis. As a group, analysts expect that TransMedics Group, Inc. will post 1.22 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on TMDX. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Canaccord Genuity Group increased their price objective on shares of TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Needham & Company LLC started coverage on shares of TransMedics Group in a research report on Wednesday, August 21st. They set a “buy” rating and a $208.00 target price for the company. Oppenheimer lifted their price target on shares of TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, August 1st. Finally, Stephens boosted their price target on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $174.30.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.